A pilot study for genome wide association study (GWAS) in patients with juvenile idiopathic arthritis (JIA) and their parents

PubMe

Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever - a randomized controlled noninferiority trial

Background: In this study, we examined the efficacy and safety of a once-daily dosage schema of colchicine compared with a twice-daily dosage schema in pediatric patients with familial Mediterranean fever (FMF). Methods: In this 24-week, multicenter, randomized controlled noninferiority trial, pediatric patients newly diagnosed with FMF carrying a homozygous or compound heterozygous mutation and not receiving any treatment were included. Patients were randomly assigned using a block randomization method to receive treatment with a once- or twice-daily dosage. Clinical and laboratory characteristics and medication side effects were recorded and compared between groups. The study was carried out in compliance with Good Clinical Practice and the Consolidated Standards for Reporting of Trials (CONSORT) statement. Results: A total of 92 patients were selected, and 79 patients completed the study. There were 42 patients in the once-daily dosage group and 37 in the twice-daily dosage group. The results indicated that the once-daily dosage was not inferior to the twice-daily dosage regarding decrease in attack frequency and duration as well as improvement in clinical findings and Mor severity scores. Alterations in laboratory findings indicating inflammation, such as erythrocyte sedimentation rate, C-reactive protein, and serum amyloid A, were similar in both groups. The rates of drug side effects were similar between the once- and twice-daily dosage groups, implying comparable safety of colchicine, with the exception of diarrhea, which was slightly higher in the once-daily dosage group. Conclusions: Using colchicine with either a once- or twice-daily dosage provides similar clinical and laboratory improvements. Considering both efficacy and safety, colchicine can be prescribed with a once-daily dosage. Trial Registration ID: ClinicalTrials.gov identifier NCT02602028. Registered 5 November 2015

Anaerobic digestion of cattle manure, corn silage and sugar beet pulp mixtures after thermal pretreatment and kinetic modeling study

WOS: 000504834400007In this study, biogas production was investigated from cattle manure (CM), corn silage (CS) and sugar beet pulp (SBP) mixtures under mesophilic conditions. In anaerobic digestion (AD), CM, CS and SBP were mixed in different ratios and the optimum mixture ratio was determined as 2:1:1, w/w/w respectively. In this mixture, biogas production was 180.5 mL/g TS. After the optimum mixing ratios of CM, CS and SBP were determined, thermal pretreatments were applied to this mixture ratio. Thermal pretreatments were performed at 100, 120, 150 and 180 degrees C with 10, 20, 30, 60 and 120 min for each temperature. Considering biogas production after thermal pretreatment, the best thermal pretreatment time was determined as 60 min for all pretreatment temperatures. The highest biogas yield was 362.1 mL/g TS in the reactor which is pretreated at 180 degrees C for 60 min. After thermal pretreatment at 180 degrees C for 60 min, the SCOD value in the reactor increased by 124.6% compared to the control. This reactor produced 100.6% higher biogas production compared to the control. In addition, the solubilization of cellulose, hemicellulose and lignin in this reactor was 38.2%, 32.9% and 23.2%, respectively. Cumulative biogas production (CBP) fitted to modified Gompertz and modified Bertalanffy models.Sivas Cumhuriyet University Scientific Research Projects Unit (CUBAP) [M-665]This research was supported by the Sivas Cumhuriyet University Scientific Research Projects Unit (CUBAP) under grant no M-665. The authors wish to thank this institution for their support

DEVELOPMENT AND VALIDATION OF JUVENILE AUTOINFLAMMATORY DISEASE MULTIDIMENSIONAL ASSESSMENT REPORT (JAIMAR)

15th Annual European Congress of Rheumatology (EULAR) -- JUN 11-14, 2014 -- Paris, FRANCEWOS: 00034691980632